Peripheral Arterial Disease Clinical Trials in New Haven, Connecticut

5 studies are recruiting for peripheral arterial disease in New Haven, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. EVERO Drug-coated Balloon (DCB) Randomized Trial

    The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero drug-coated balloon [DCB]) in the treatment of the femoropopliteal artery le…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Yale New Haven Hospital, New Haven, Connecticut
    Locations
    10 in total
    Run by
    Cook Research Incorporated

    See if you can join NCT07144150 on ClinicalTrials.gov

  2. CRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions

    The primary goal of the study is to obtain effect size data on the use of Shockwave Intravascular Lithotripsy (IVL) technology in calcified common femoral lesions in patients with peripheral artery disease for a series of endpoints, including target lesion revascularization and health status, to en…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Yale New Haven Health, New Haven, Connecticut
    Locations
    2 in total
    Run by
    Yale University

    See if you can join NCT05145478 on ClinicalTrials.gov

  3. SELUTION4BTK Trial

    This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Yale University, New Haven, Connecticut
    Locations
    48 in total
    Run by
    M.A. Med Alliance S.A.

    See if you can join NCT05055297 on ClinicalTrials.gov

  4. PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

    A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.

    Stage
    Not phased
    Ages
    18 to 95
    Site
    Yale University, New Haven, Connecticut
    Locations
    30 in total
    Run by
    LimFlow, Inc.

    See if you can join NCT05313165 on ClinicalTrials.gov

  5. Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

    The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral artery disease.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Yale School of Medicine, New Haven, Connecticut
    Locations
    70 in total
    Run by
    Population Health Research Institute

    See if you can join NCT04774159 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.